Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection

摘要: Lyme disease is the leading tick-borne in USA. Whereas majority of patients with early can be cured standard treatment, some suffer from chronic fatigue and joint muscular pain despite a syndrome called posttreatment syndrome. Although cause unclear, ineffective killing Borrelia burgdorferi persisters by current antibiotics one possible explanation. We took advantage our recently developed high-throughput viability assay screened National Cancer Institute compound library collection consisting 2526 compounds against stationary phase B. burgdorferi. identified top 30 new active hits, including six anthracycline daunomycin 3-oxime, dimethyldaunomycin, daunomycin, NSC299187, NSC363998 nogalamycin, along other compounds, prodigiosin, mitomycin, nanaomycin dactinomycin, as having excellent activity culture. The or anthraquinone which are known to have both anti-cancer antibacterial activities, also had high growing low minimum inhibitory concentration. Future studies on structure-activity relationship mechanisms action anthracyclines/anthraquinones warranted. In addition, drug combination class eradicate vitro animal models needed determine if they improve treatment disease.